[
  {
    "ts": "2026-01-06T04:26:57+00:00",
    "headline": "BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)",
    "summary": "BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...",
    "url": "https://finance.yahoo.com/news/bioinvent-keytruda-ovarian-cancer-signal-042657084.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "38f0988c-9083-3f1a-b675-cc4037bc12e6",
      "content": {
        "id": "38f0988c-9083-3f1a-b675-cc4037bc12e6",
        "contentType": "STORY",
        "title": "BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)",
        "description": "",
        "summary": "BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...",
        "pubDate": "2026-01-06T04:26:57Z",
        "displayTime": "2026-01-06T04:26:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bioinvent-keytruda-ovarian-cancer-signal-042657084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bioinvent-keytruda-ovarian-cancer-signal-042657084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BOVNF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:13:00+00:00",
    "headline": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
    "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
    "url": "https://finance.yahoo.com/news/tigit-inhibitors-drugs-clinical-trials-141300202.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c06f4821-64a0-353e-9af8-ddceff8c3bc5",
      "content": {
        "id": "c06f4821-64a0-353e-9af8-ddceff8c3bc5",
        "contentType": "STORY",
        "title": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
        "description": "",
        "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
        "pubDate": "2026-01-06T14:13:00Z",
        "displayTime": "2026-01-06T14:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tigit-inhibitors-drugs-clinical-trials-141300202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tigit-inhibitors-drugs-clinical-trials-141300202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RCUS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]